

References

I-175

1. Kirzinger L, Boy S, Marienhagen J, et al. Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. *PLoS ONE*. 2016;1-14.
2. Fougner SL, Bollerslev J, Svartberg J, et al. Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. *European Journal of Endocrinology*. 2012;229-235.
3. Kurumboor P, Palniswami KN, Pramil K, et al. Octreotide Does Not Prevent Pancreatic Fistula Following Pancreatoduodenectomy in Patients with Soft Pancreas and Non-dilated Duct: A Prospective Randomized Controlled Trial. *J Gastrointest Surg*. 2015;2038–2044.
4. MICRO MEDEX®SOLUTIONS Compendia. 2017. Octreotide acetate.
5. MICRO MEDEX®SOLUTIONS Compendia. 2017. Lanreotide Acetate.
6. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. 2017. Octreotide.
7. National Comprehensive Cancer Network® (NCCN) Drugs and Biologics Compendium. Octreotide acetate.
8. National Comprehensive Cancer Network® 2017 (NCCN) Drugs and Biologics Compendium. Lanreotide.
9. SOMATULINE® DEPOT (lanreotide) [package insert]. Basking Ridge, NJ. Ipsen Biopharmaceuticals, Inc. 2014.
10. Sandostatin® (octreotide acetate) [package insert]. East Hanover, NJ. Novartis Pharma Stein AG. 2012.
11. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.